Biochemical markers for blood-brain barrier dysfunction in acute ischemic stroke correlate with evolution and outcome

European Neurology

Volumn 65, Issue 1, 2011, Pages 23-31

  Brouns, Raf ^a,c,d   Wauters, Annick ^e   De Surgeloose, Didier ^e   Mariën, Peter ^b,c   De Deyn, Peter P ^c,d  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c Department of Neurology   (United States)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

Albumin ratio; Cerebrospinal fluid; Matrix Metalloproteinase 9; Stroke; Stroke evolution; Stroke outcome

Indexed keywords

ALBUMIN; BIOCHEMICAL MARKER; GELATINASE B;

ACUTE DISEASE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN DAMAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME KINETICS; FEMALE; HUMAN; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANKIN SCALE; STROKE; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; SERUM ALBUMIN; STROKE; TREATMENT OUTCOME;

EID: 78649708318     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321965     Document Type: Article

References (43)

1. Fishman RA: Brain edema. N Engl J Med 1975; 293:706-711.
2. Brouns R, De Deyn PP: The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg 2009; 111: 483-495.
3. Heo JH, Han SW, Lee SK: Free radicals as triggers of brain edema formation after stroke. Free Radic Biol 2005; 39: 51-70.
4. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH: Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001; 21: 1393-1400.
5. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, Milne GL, Hubbard J, Lee H, Stevenson E, Lederer M, Furie KL: Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008; 39:100-104.
6. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, Chan PH: Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999; 19: 1020-1028. (Pubitemid 30173725)
7. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J: MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-1126.
8. Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH, Park TS: Leukocyte-derived matrix metalloprotein-ase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol 2005; 289:H558-H568.
9. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR: Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997; 238: 53-56.
10. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metallo-proteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-633.
11. Wagner S, Nagel S, Kluge B, Schwab S, Heiland S, Koziol J, Gardner H, Hacke W: Topographically graded postischemic presence of metalloproteinases is inhibited by hypothermia. Brain Res 2003; 984: 63-75.
12. Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A: The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005; 36: 1921-1926.
13. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32:1759-1766.
14. Kuroiwa T, Ting P, Martinez H, Klatzo I: The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion. Acta Neuropathol 1985; 68:122-129.
15. Belayev L, Busto R, Zhao W, Ginsberg MD: Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 1996; 739: 88-96.
16. Huang ZG, Xue D, Preston E, Karbalai H, Buchan AM: Biphasic opening of the blood-brain barrier following transient focal ischemia: effects of hypothermia. Can J Neurol Sci 1999; 26: 298-304.
17. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ: Microvascular basal lamina antigens disappear during cerebral ischemia and reper-fusion. Stroke 1995; 26: 2120-2126.
18. Kastrup A, Engelhorn T, Beaulieu C, de Crespigny A, Moseley ME: Dynamics of cerebral injury, perfusion, and blood-brain barrier changes after temporary and permanent middle cerebral artery occlusion in the rat. J Neurol Sci 1999; 166: 91-99.
19. Temiz C, Dogan A, Baskaya M, Dempsey R: Effect of difluoromethylornithine on reperfusion injury after temporal middle cerebral artery occlusion. J Clin Neurosci 2005; 12: 449-452.
20. Lorberboym M, Lampl Y, Sadeh M: Correlation of 99mTc-DTPA SPECT of the blood-brain barrier with neurologic outcome after acute stroke. J Nucl Med 2003; 44: 1898-1904.
21. *-permeability magnetic resonance imaging. Ann Neurol 2007; 62: 170-176.
22. Kidwell CS, Latour L, Saver JL, Alger JR, Starkman S, Duckwiler G, Jahan R, Vinuela F, Kang DW, Warach S: Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008; 25: 338-343.
23. Hjort N, Wu O, Ashkanian M, Solling C, Mouridsen K, Christensen S, Gyldensted C, Andersen G, Ostergaard L: MRI detection of early blood-brain barrier disruption: parenchymal enhancement predicts focal hemorrhagic transformation after thrombolysis. Stroke 2008; 39:1025-1028.
24. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S: Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004; 56: 468-477.
25. Hornig CR, Busse O, Buettner T, Dorndorf W, Agnoli A, Akengin Z: CT contrast enhancement on brain scans and blood-CSF barrier disturbances in cerebral ischemic infarction. Stroke 1985; 16:268-273.
26. Al-Kassab S, Skyhoj OT, Skriver EB: Blood-brain barrier integrity in patients with cerebral infarction investigated by computed tomography and serum-CSF-albumin. Acta Neurol Scand 1981; 64:438-445.
27. Suzuki S, Kelley RE, Reyes-Iglesias Y, Alfonso VM, Dietrich WD: Cerebrospinal fluid and peripheral white blood cell response to acute cerebral ischemia. South Med J 1995; 88: 819-824.
28. Niebroj-Dobosz I, Mariam AG, Lukasiuk M, Rafalowska J: Blood-cerebrospinal fluid barrier integrity in cerebral infarction. Neuropatol Pol 1992; 30:29-33.
29. Hornig CR, Busse O, Dorndorf W, Kaps M: Changes in CSF blood-brain barrier parameters in ischaemic cerebral infarction. J Neurol 1983; 229: 11-16.
30. Brouns R, Sheorajpanday R, Wauters A, De Surgeloose D, Marien P, De Deyn PP: Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. Clin Chim Acta 2008; 397: 27-31.
31. Brouns R, Van Den Bossche J, De Surgeloose D, Sheorajpanday R, De Deyn PP: Clinical and biochemical diagnosis of small-vessel disease in acute ischemic stroke. J Neurol Sci 2009; 285: 185-190.
32. Brouns R, Heylen E, Sheorajpanday R, Willemse JL, Kunnen J, De Surgeloose D, Hendriks DF, De Deyn PP: Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients. Clin Neurol Neurosurg 2009; 111: 165-170.
33. Brouns R, De Vil B, Cras P, De Surgeloose D, Marien P, De Deyn PP: Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. Clin Chem 2010; 56: 451-458.
34. Brouns R, Sheorajpanday R, Kunnen J, De Surgeloose D, De Deyn PP: Clinical, biochemical and neuroimaging parameters after thrombolytic therapy predict long-term stroke outcome. Eur Neurol 2009; 62: 9-15.
35. Brouns R, Marescau B, Possemiers I, Sheorajpanday R, De Deyn PP: Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem Res 2009; 34: 1642-1649.
36. Brouns R, Van Hemelrijck A, Drinkenburg W, Van Dam D, De Surgeloose D, De Deyn PP: Excitatory amino acids and monoaminergic neurotransmitters in cerebrospinal fluid of acute ischemic stroke patients. Neurochem Int 2010; 56: 865-870.
37. Brouns R, Wauters A, Van De Vijver G, De Surgeloose D, Sheorajpanday R, De Deyn PP: Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome. Clin Chem Lab Med 2010; 48:383-390.
38. Brouns R, Heylen E, Willemse JL, Sheorajpanday R, De Surgeloose D, Verkerk R, De Deyn PP, Hendriks DF: The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 2010; 8: 75-80.
39. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457-507.
40. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm L, Wikkelso C: Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993; 33:129-133. (Pubitemid 23100537)
41. Triage Stroke Panel: Product insert version 22662en Rev. C 2006. pp. 13-23.
42. Birschel P, Ellul J, Barer D: Progressing stroke: towards an internationally agreed def inition. Cerebrovasc Dis 2004; 17: 242-252. (Pubitemid 38529205)
43. Weisscher N, Vermeulen M, Roos YB, de Haan RJ: What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2? J Neurol 2008; 255:867-874.